Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II
- 1 January 2010
- journal article
- Published by Elsevier in Value in Health
- Vol. 13 (1) , 8-13
- https://doi.org/10.1111/j.1524-4733.2009.00660.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Welfarism vs. extra-welfarismJournal of Health Economics, 2007
- Surplus Appropriation from R&D and Health Care Technology Assessment ProceduresPublished by National Bureau of Economic Research ,2006
- Health Care Vouchers — A Proposal for Universal CoverageNew England Journal of Medicine, 2005
- Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and PatentsInternational Journal of Health Economics and Management, 2003
- Inconsistencies in the "Societal Perspective" on Costs of the Panel on Cost-Effectiveness in Health and MedicineMedical Decision Making, 1999
- Patent Buyouts: A Mechanism for Encouraging InnovationThe Quarterly Journal of Economics, 1998
- Economic foundations of cost-effectiveness analysisJournal of Health Economics, 1997
- Consumer-Choice Health PlanNew England Journal of Medicine, 1978